Adjuvant radiotherapy might not be the best treatment for mesothelioma sufferers because researchers at Duke and Stanford found that this therapy does not help patients live longer. The researchers analyzed a database of pleural mesothelioma patients at Duke and a national registry of patients. The research looked at the outcomes[…]
Pleural Mesothelioma
Doctors Should Use Pleurectomy Decortication Surgery Over Extrapleural Pneumonectomy Surgery
A study looking at many patients with pleural mesothelioma found that there is not enough of a survival advantage to support the use of extrapleural pneumonectomy surgery (EPP). The study was done at the MD Anderson Cancer Center at the University of Texas. EPP is the most aggressive surgery for[…]
Mesothelioma Patients with High Levels of the PD-L1 Protein Have Shorter Survival
Unfortunately for mesothelioma patients with high levels of the PD-L1 protein, they have a worse overall survival compared to patients who have lower levels. A European study looking at 200 patients wanted to see if PD-L1 and PD-1, popular targets for immunotherapy drugs, impact survival independently without immunotherapy drugs present.[…]
Tri-Modality Therapy Triples Survival Compared to Chemotherapy and Surgery Alone
A very aggressive mesothelioma treatment is proving to be more beneficial compared to just chemotherapy and surgery alone. The more aggressive therapy utilizes multiple techniques creating a more successful treatment in certain patients. Mesothelioma treatment needs to be aggressive because it is a tough to treat and aggressive cancer. People[…]
Pleurectomy/Decortication Surgery Can Improve Quality of Life, Even in Patients with Declining Lung Function
Researchers at the Hyogo College of Medicine have found that pleurectomy/decortication surgery can improve quality of life in mesothelioma patients, even if they have declining lung function. The researchers looked at 45 patients who received pleurectomy/decortication surgery between the years 2014 and 2018. After the patients received surgery, lung function[…]
The Two Major Mesothelioma Surgeries Have Similar Death Rates
Japanese researchers have found that the main two types of surgery for mesothelioma have similar risks of death. The surgeries either remove the diseased lung lining and one of the lungs or just the lining. Doctors do not agree what surgery is best for mesothelioma patients, but both surgeries have[…]
A Combination of Tremelimumab and Durvalumab Can Extend Mesothelioma Survival
An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan drug status to treat liver cancer in the last year. The best results in the mesothelioma study were seen in[…]
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma (SCITH-MESO)
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
Second Mesothelioma Surgeries Can Help Extend Lives and Improve Quality of Life of Patients
Surgery can be hard on the body, but it can help some mesothelioma patients if done a second time. People could still have a good quality of life and even an extended survival if they undergo the aggressive surgery. This surgery is not common and would not be recommended for[…]
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
The purpose of the Dielectrics Properties of Thoracic Malignancies Study (DPTMS) is to provide a wealth of knowledge for investigators involved in establishing a new and effective treatment for a variety of solid tumors using tumor treatment fields. It is intended to provide biospecimen (tumor/healthy) together with demographic data (age, sex, race, occupational history, and other epidemiologic information), and clinical data (stage, treatment, survival information, and annotated CT’s). Our specific aims are to test the following hypotheses: 1) Electric properties of thoracic tumors differ from electric properties of surrounding healthy tissue 2) Different tumor types will have different electric properties 3) Electric properties of individual tumors are heterogeneous 4) Electric properties of tumors are related to the structure and composition of the underlying tissue 5) Use of standard medical imaging data (CT) will permit mapping of electric properties.
